What's in Risk Factor Modification Centre's pipeline?

Risk Factor Modification Centre has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Risk Factor Modification Centre's portfolio?

Top competitors by shared drug class: LanZhou University, Seoul National University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/risk-factor-modification-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Risk Factor Modification Centre — Portfolio Competitive Intelligence Brief

Risk Factor Modification Centre pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
American ginseng root / polysaccharides	American ginseng root / polysaccharides	phase 3	Herbal extract / Immunomodulator		Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

LanZhou University · 1 shared drug class
Seoul National University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Risk Factor Modification Centre:

Cite this brief

Drug Landscape (2026). Risk Factor Modification Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/risk-factor-modification-centre. Accessed 2026-05-15.